Skip to main
ACHV
ACHV logo

ACHV Stock Forecast & Price Target

ACHV Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 88%
Buy 13%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Achieve Life Sciences Inc. presents a positive outlook due to the differentiated profile of cytisinicline, which demonstrates improved safety and has the potential to disrupt the smoking cessation market. The statistically significant abstinence results from the pilot P2 ORCA-V1 trial, with an odds ratio of 2.6, indicate broad potential clinical utilization among the 11 million U.S. adults and 2 million middle/high school e-cigarette users interested in quitting. Moreover, management's collaboration with the FDA on a long-term study and the planned initiation of the ORCA OL trial in Q2 2024 position the company favorably for future growth and approval of cytisinicline for vaping cessation.

Bears say

Achieve Life Sciences faces several downside risks that contribute to a negative outlook on its stock, including the potential failure of the ORCA-3 Phase 3 trial to meet endpoints, slow enrollment in ORCA trials, and limited market penetration of cytisinicline due to the generic availability of Chantix. The company's recent first-quarter 2024 report indicated an earnings per share (EPS) of ($0.26), which fell short of both its estimates and the broader market consensus of ($0.24), highlighting ongoing financial challenges. Despite the extensive clinical evidence supporting cytisinicline, its lack of launch in major markets after over 20 years of being on the market poses significant concerns regarding its commercial viability.

ACHV has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 88% of analysts recommend a Strong Buy, 13% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Achieve Life Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Achieve Life Sciences (ACHV) Forecast

Analysts have given ACHV a Strong Buy based on their latest research and market trends.

According to 8 analysts, ACHV has a Strong Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Achieve Life Sciences (ACHV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.